Mesa Laboratories (MLAB) 10-Q 5 Aug 24 2025 Q1 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	3 Months Ended
	Jun. 30, 2024	Jul. 31, 2024
Document Information [Line Items]
Entity Central Index Key	0000724004
Entity Registrant Name	MESA LABORATORIES INC /CO
Amendment Flag	false
Current Fiscal Year End Date	--03-31
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2025
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Jun. 30, 2024
Document Transition Report	false
Entity File Number	0-11740
Entity Incorporation, State or Country Code	CO
Entity Tax Identification Number	84-0872291
Entity Address, Address Line One	12100 West Sixth Avenue
Entity Address, City or Town	Lakewood
Entity Address, State or Province	CO
Entity Address, Postal Zip Code	80228
City Area Code	303
Local Phone Number	987-8000
Title of 12(b) Security	Common Stock, no par value
Trading Symbol	MLAB
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		5,409,163

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($) $ in Thousands	Jun. 30, 2024	Mar. 31, 2024
Cash and cash equivalents	$ 28,472	$ 28,214
Accounts receivable, less allowance for doubtful accounts of $1,057 and $1,321, respectively	35,568	39,055
Inventories	31,767	32,675
Prepaid expenses and other current assets	10,883	9,408
Total current assets	106,690	109,352
Noncurrent assets:
Property, plant and equipment, net of accumulated depreciation of $22,574 and $22,519 respectively	31,402	31,766
Deferred tax asset	1,281	1,292
Other assets	11,807	10,538
Intangible assets	109,459	113,752
Goodwill	179,722	180,096
Total assets	440,361	446,796
LIABILITIES AND STOCKHOLDERS’ EQUITY
Accounts payable	5,659	6,041
Accrued payroll and benefits	8,338	9,935
Unearned revenues	14,634	15,478
Term loan, current portion	3,750	0
Other accrued expenses	22,484	12,858
Total current liabilities	54,865	44,312
Noncurrent liabilities:
Deferred tax liability	19,689	19,780
Other	6,581	15,613
Revolving line of credit	42,000	50,500
Noncurrent portion	69,603	0
Convertible senior notes, net of debt issuance costs	96,896	171,198
Total liabilities	289,634	301,403
Stockholders’ equity:
Common stock, no par value; authorized 25,000,000 shares; issued and outstanding, 5,409,155 and 5,394,491 shares, respectively	345,999	343,642
(Accumulated deficit)	(180,969)	(183,494)
Accumulated other comprehensive (loss)	(14,303)	(14,755)
Total stockholders’ equity	150,727	145,393
Total liabilities and stockholders’ equity	440,361	446,796
Customer Relationships [Member]
Noncurrent assets:
Intangible assets	82,238	85,383
Other Intangible Assets [Member]
Noncurrent assets:
Intangible assets	$ 27,221	$ 28,369

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - USD ($) $ / shares in Thousands, $ in Thousands	Jun. 30, 2024	Mar. 31, 2024
Allowance for doubtful accounts receivable	$ 1,057	$ 1,321
Property, plant, and equipment accumulated depreciation	$ 22,574	$ 22,519
Common stock, no par value (in dollars per share)	$ 0	$ 0
Common stock, authorized (in shares)	25,000,000	25,000,000
Common stock, issued (in shares)	5,409,155	5,394,491
Common stock, outstanding (in shares)	5,409,155	5,394,491

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) shares in Thousands, $ in Thousands		3 Months Ended
		Jun. 30, 2024	Jun. 30, 2023
Revenues	[1]	$ 58,170	$ 50,645
Cost of revenues		20,921	19,462
Gross profit		37,249	31,183
Operating expense:
Selling		10,116	8,976
Research and development		4,735	4,811
Total operating expense		31,669	31,847
Operating income (loss)		5,580	(664)
Nonoperating expense:
Interest expense and amortization of debt issuance costs		2,842	1,048
Gain on extinguishment of convertible notes		(3,197)	0
Other expense (income), net		2,030	(775)
Total nonoperating expense, net		1,675	273
Earnings (loss) before income taxes		3,905	(937)
Income tax expense (benefit)		517	(388)
Net (loss) income		$ 3,388	$ (549)
Earnings (loss) per share:
Basic earnings (loss) per share (in dollars per share)		$ 0.63	$ (0.1)
Diluted earnings (loss) per share (in dollars per share)		$ 0.62	$ (0.1)
Weighted-average common shares outstanding:
Basic (in shares)		5,397	5,372
Diluted (in shares)		5,424	5,372
Product [Member]
Revenues		$ 58,170	$ 50,645
Service [Member]
Operating expense:
General and administrative		$ 16,818	$ 18,060
[1]Intersegment revenues are not significant and are eliminated to arrive at consolidated totals.

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Comprehensive (Loss) - USD ($) $ in Thousands	3 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Net income (loss)	$ 3,388	$ (549)
Other comprehensive income (loss):
Foreign currency translation adjustments	452	(6,661)
Comprehensive income (loss)	$ 3,840	$ (7,210)

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($) $ in Thousands	Common Stock [Member]	Retained Earnings [Member]	AOCI Attributable to Parent [Member]		Total
Balance (in shares) at Mar. 31, 2023	5,369,466
Balance at Mar. 31, 2023	$ 332,076	$ 74,199	$ (12,795)	[1]	$ 393,480
Exercise of stock options and vesting of restricted stock units (in shares)	20,074
Exercise of stock options and vesting of restricted stock units	$ 52				52
Tax withholding on vesting of restricted stock units (in shares)	(5,260)
Tax withholding on vesting of restricted stock units	$ (712)	0	0		(712)
Dividends paid, $0.16 per share		(859)			(859)
Stock-based compensation expense	$ 2,968				2,968
Foreign currency translation			(6,661)	[1]	(6,661)
Net income		(549)			(549)
Balance (in shares) at Jun. 30, 2023	5,384,280
Balance at Jun. 30, 2023	$ 334,384	72,791	(19,456)	[1]	$ 387,719
Balance (in shares) at Mar. 31, 2024	5,394,491				5,394,491
Balance at Mar. 31, 2024	$ 343,642	(183,494)	(14,755)	[1]	$ 145,393
Exercise of stock options and vesting of restricted stock units (in shares)	20,858
Exercise of stock options and vesting of restricted stock units	$ 0				0
Tax withholding on vesting of restricted stock units (in shares)	(6,194)
Tax withholding on vesting of restricted stock units	$ (571)	0	0		(571)
Dividends paid, $0.16 per share		(863)			(863)
Stock-based compensation expense	$ 2,928				2,928
Foreign currency translation			452	[1]	452
Net income		3,388			$ 3,388
Balance (in shares) at Jun. 30, 2024	5,409,155				5,409,155
Balance at Jun. 30, 2024	$ 345,999	$ (180,969)	$ (14,303)	[1]	$ 150,727
[1]Accumulated Other Comprehensive [(Loss) Income].

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Stockholders' Equity (Unaudited) (Parentheticals) - $ / shares	3 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Dividends paid, per share (in dollars per share)	$ 0.16	$ 0.16

Condensed Consolidated Statem_5

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Cash flows from operating activities:
Net income (loss)	$ 3,388	$ (549)
Adjustments to reconcile net income to net cash from operating activities:
Depreciation of property, plant and equipment	1,404	914
Amortization of acquisition-related intangibles	4,061	7,220
Stock-based compensation expense	2,928	2,968
Gain on extinguishment of convertible notes	(3,197)	0
Amortization of step-up in inventory basis	778	0
Other	1,409	513
Cash from changes in operating assets and liabilities:
Accounts receivable, net	3,482	6,456
Inventories	(671)	(1,244)
Prepaid expenses and other assets	969	(2,448)
Accounts payable	(388)	(539)
Accrued liabilities and taxes payable	(2,811)	(3,217)
Unearned revenues	(919)	(135)
Net cash provided by operating activities	10,433	9,939
Cash flows from investing activities:
Purchases of property, plant and equipment	(891)	(270)
Net cash (used in) investing activities	(891)	(270)
Cash flows from financing activities:
Proceeds from the issuance of debt, net	73,465	0
Repayment of debt	(9,438)	(8,000)
Repurchase of convertible debt	(71,250)	0
Dividends paid	(863)	(859)
Other financing, net	(1,023)	(660)
Net cash (used in) financing activities	(9,109)	(9,519)
Effect of exchange rate changes on cash and cash equivalents	(175)	(684)
Net increase (decrease) in cash and cash equivalents	258	(534)
Cash and cash equivalents at beginning of period	28,214	32,910
Cash and cash equivalents at end of period	$ 28,472	$ 32,376

Note 1 - Description of Busines

Note 1 - Description of Business and Summary of Significant Accounting Policies	3 Months Ended
	Jun. 30, 2024
Notes to Financial Statements
Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block]	Note 1 . Description of Business and Summary of Significant Accounting Policies Description of Business In this quarterly report on Form 10 We are a global leader in the design and manufacture of life sciences tools and critical quality control solutions for regulated applications in the pharmaceutical, healthcare, and medical device industries. We offer products and services to help our customers ensure product integrity, increase patient and worker safety, and improve the quality of life throughout the world. We have manufacturing operations in the United States and Europe, and our products are marketed by our sales personnel in North America, Europe, and Asia Pacific, and by independent distributors in these areas as well as throughout the rest of the world. We prefer markets in which we can establish a strong presence and achieve high gross profit margins. As of June 30, 2024 four ● Sterilization and Disinfection Control ● Clinical Genomics ● Biopharmaceutical Development ● Calibration Solutions Basis of Presentation The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission and in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) for interim financial information. In the opinion of management, such unaudited information includes all adjustments, consisting of normal recurring adjustments necessary for the fair statement of our financial position and results of operations. The results of operations for interim periods are not may not no 10 10 March 31, 2024 Our fiscal year ends on March 31. Risks and Uncertainties The preparation of financial statements requires the use of estimates and assumptions that affect the reported amounts of assets and liabilities at the reporting date and revenues and expenses during the reporting periods. These estimates represent management's judgment about the outcome of future events. The global business environment continues to be impacted by cost pressures, the overall effects of economic uncertainty on customers' purchasing patterns, high interest rates, and other factors. It is not Recently Issued Accounting Pronouncements In November 2023, No. 2023 07, 280 No. 2023 07 280 December 15, 2023 ( 2025 December 15, 2024 ( 2026 In December 2023, No. 2023 09, 740 No. 2023 09, December 15, 2024 ( 2026 We have reviewed all recently issued accounting pronouncements and have concluded that, other than as described above, they are either not not

Note 2 - Significant Transactio

Note 2 - Significant Transactions	3 Months Ended
	Jun. 30, 2024
Notes to Financial Statements
Significant Transactions [Text Block]	Note 2 . Significant Transactions GKE - Fiscal Year 2024 We acquired 100% of the outstanding shares of GKE GmbH and SAL GmbH effective October 16, 2023, December 31, 2023, GKE develops, manufactures and sells a highly competitive portfolio of chemical sterilization indicators, biologics, and process challenge devices to protect patient safety across global healthcare markets. GKE is included in our Sterilization and Disinfection Control ("SDC") division, and GKE's strengths in chemical indictors are complementary to SDC's strengths in biologic indicators, as chemical and biologic indicators are used in the same sterility validation workflows. Additionally, GKE’s healthcare-focused commercial capabilities in Europe and Asia greatly expand our reach in the healthcare markets in those geographies. We are working to obtain regulatory 510 We finalized our purchase price accounting of GKE during fiscal year 2024. June 30, 2024 18 During the three June 30, 2024 three June 30, 2024

Note 3 - Revenue

Note 3 - Revenue	3 Months Ended
	Jun. 30, 2024
Notes to Financial Statements
Revenue from Contract with Customer [Text Block]	Note 3. We develop, manufacture, market, sell and maintain life sciences tools and quality control instruments and related consumables. Hardware sales include physical products such as instruments used for molecular and genetic analysis, protein synthesizers, medical meters, wireless sensor systems, data loggers, and process challenge devices. Hardware sales may Consumables are typically used on a one Revenues from hardware and consumables are recognized upon transfer to the customer, typically at the point of shipment. We also offer maintenance, calibration, and testing service contracts. These contracts result in revenues recognized over time, for example, when we are obligated to perform labor and replace parts on an as-needed basis over a contractually specified period, or at a point in time, upon completion of a specific, discrete service. In many cases, our contracts contain both revenues recognized over time and revenues recognized at a point in time. We evaluate our revenues internally based on business division and the nature of goods and services provided. The following tables present disaggregated revenues for the three June 30, 2024 2023 Three Months Ended June 30, 2024 Sterilization and Disinfection Control (1) Clinical Genomics Biopharmaceutical Development Calibration Solutions Total Consumables $ 20,396 $ 8,112 $ 3,922 $ 580 $ 33,010 Hardware and software 169 2,183 4,837 6,886 14,075 Services 2,392 1,109 3,249 4,335 11,085 Total revenues $ 22,957 $ 11,404 $ 12,008 $ 11,801 $ 58,170 ( 1 three June 30, 2024 . Three Months Ended June 30, 2023 Sterilization and Disinfection Control Clinical Genomics Biopharmaceutical Development Calibration Solutions Total Consumables $ 13,707 $ 8,769 $ 4,486 $ 509 $ 27,471 Hardware and software 81 3,427 2,691 7,078 13,277 Services 2,139 1,173 2,712 3,873 9,897 Total revenues $ 15,927 $ 13,369 $ 9,889 $ 11,460 $ 50,645 Revenues from external customers are attributed to individual countries based upon the locations to which the products are shipped or exported, or locations where services are performed, as follows: Three Months Ended June 30, 2024 2023 United States $ 26,861 $ 26,537 China 6,559 6,113 Other 24,750 17,995 Total revenues $ 58,170 $ 50,645 Other than China, no 10% three June 30, 2024 2023 Contract Balances Our contracts have varying payment terms and conditions. Some customers prepay for products and services, resulting in unearned revenues or customer deposits, called contract liabilities. Short-term contract liabilities are included within unearned revenues in the accompanying unaudited Condensed Consolidated Balance Sheets, and long-term contract liabilities are included within other noncurrent liabilities in the accompanying unaudited Condensed Consolidated Balance Sheets. The significant majority of our revenues and related receivables and contract liabilities are generated from contracts with customers with original durations of 12 A summary of contract liabilities is as follows: Contract liabilities as of March 31, 2024 $ 15,686 Prior year liabilities recognized in revenues during the three months ended June 30, 2024 (3,805 ) Contract liabilities added during the three months ended June 30, 2024, net of revenues recognized 2,877 Contract liabilities as of June 30, 2024 $ 14,758

Note 4 - Fair Value Measurement

Note 4 - Fair Value Measurements	3 Months Ended
	Jun. 30, 2024
Notes to Financial Statements
Fair Value Disclosures [Text Block]	Note 4. Our financial instruments consist primarily of cash and cash equivalents, trade accounts receivable, obligations under trade accounts payable, and debt. Due to their short-term nature, the carrying values for cash and cash equivalents, trade accounts receivable, and trade accounts payable approximate fair value; they are classified within Level 1 The financial instruments that subject us to the highest concentration of credit risk are cash and accounts receivable. We maintain relationships and cash deposits at multiple banking institutions across the world in an effort to diversify and reduce risk of loss. Concentration of credit risk with respect to accounts receivable is limited to customers to whom we make significant sales. No customers accounted for more than 10% June 30, 2024 On April 5, 2024, August 15, 2025 ( 7. June 30, 2024 2 The estimated fair value and carrying value of the Notes were as follows: June 30, 2024 March 31, 2024 Carrying Value Fair Value (Level 2) Carrying Value Fair Value (Level 2) Notes $ 96,896 $ 92,016 $ 171,198 $ 163,013 The carrying amount of the term loan and revolving line of credit (together, the "Credit Facility") on the Condensed Consolidated Balance Sheets approximates fair value due to the variable interest rate pricing on the debt with the balance bearing an interest rate approximating current market rates. For the GKE acquisition, we held back approximately $9,200 (at June 30, 2024 18 3 During fiscal year 2023, 11. not 3 Amounts recognized or disclosed at fair value in the unaudited condensed consolidated financial statements on a nonrecurring basis include the initial recognition and disclosure of most assets and liabilities purchased in business acquisitions and any related measurement period adjustments. Additionally, assets such as property and equipment, operating lease assets, goodwill and other intangible assets are adjusted to fair value if determined to be impaired. We recorded no three June 30, 2024 June 30, 2023 3 There were no three June 30, 2024 June 30, 2023

Note 5 - Supplemental Informati

Note 5 - Supplemental Information	3 Months Ended
	Jun. 30, 2024
Notes to Financial Statements
Supplemental Balance Sheet Disclosures [Text Block]	Note 5. Inventories consisted of the following: June 30, 2024 March 31, 2024 Raw materials $ 19,031 $ 18,335 Work in process 682 1,256 Finished goods 12,054 13,084 Total inventories $ 31,767 $ 32,675 Prepaid expenses and other current assets consisted of the following: June 30, 2024 March 31, 2024 Prepaid expenses $ 3,928 $ 2,932 Deposits 1,514 1,898 Prepaid income taxes 1,798 1,237 Other current assets 3,643 3,341 Total prepaid expenses and other current assets $ 10,883 $ 9,408 Accrued payroll and benefits consisted of the following: June 30, 2024 March 31, 2024 Bonus payable $ 2,175 $ 3,838 Wages and paid-time-off payable 3,402 3,072 Payroll related taxes 2,223 1,956 Other benefits payable 538 1,069 Total accrued payroll and benefits $ 8,338 $ 9,935 Other accrued expenses consisted of the following: June 30, 2024 March 31, 2024 Accrued business taxes $ 5,268 $ 5,557 Current operating lease liabilities 2,940 2,986 Income taxes payable 1,569 1,615 Current acquisition-related holdbacks 9,384 436 Other 3,323 2,264 Total other accrued expenses $ 22,484 $ 12,858 The increase in other accrued expenses is primarily due to the reclassification of the GKE acquisition consideration held back to current from long term as of June 30, 2024. Other noncurrent liabilities consisted of the following: June 30, 2024 March 31, 2024 Noncurrent operating lease liabilities $ 6,299 $ 6,613 Noncurrent acquisition-related holdbacks 158 8,792 Other 124 208 Total other noncurrent liabilities $ 6,581 $ 15,613 The decrease in other noncurrent liabilities is primarily due to the reclassification of the GKE acquisition consideration held back to current from long term as of June 30, 2024. Three Months Ended June 30, 2024 2023 Depreciation expense in cost of revenues $ 862 $ 674 Depreciation expense in operating expense 542 240 Total depreciation expense $ 1,404 $ 914 $304 of the increase in depreciation expense is attributable to GKE.

Note 6 - Goodwill and Intangibl

Note 6 - Goodwill and Intangible Assets, Net	3 Months Ended
	Jun. 30, 2024
Notes to Financial Statements
Goodwill and Intangible Assets Disclosure [Text Block]	Note 6. Finite-lived intangible assets consisted of the following: June 30, 2024 March 31, 2024 Gross Carrying Amount Accumulated Amortization Net Carrying Amount Gross Carrying Amount Accumulated Amortization Net Carrying Amount Customer relationships $ 189,708 $ (107,470 ) $ 82,238 $ 189,911 $ (104,528 ) $ 85,383 Other intangibles 61,140 (33,919 ) 27,221 61,161 (32,792 ) 28,369 Total finite-lived intangible assets $ 250,848 $ (141,389 ) $ 109,459 $ 251,072 $ (137,320 ) $ 113,752 Amortization expense for finite-lived intangible assets was as follows: Three Months Ended June 30, 2024 2023 Amortization in cost of revenues $ 647 $ 1,728 Amortization in general and administrative 3,414 5,492 Total amortization expense $ 4,061 $ 7,220 For the following fiscal years ending March 31, Fiscal Year Amortization Expense Remainder of 2025 $ 13,289 2026 16,975 2027 16,319 2028 15,731 2029 15,182 The change in the carrying amount of goodwill was as follows: Sterilization and Disinfection Control Clinical Genomics Biopharmaceutical Development Calibration Solutions Total March 31, 2024 $ 79,430 $ 16,940 $ 46,515 $ 37,211 180,096 Effect of foreign currency translation (494 ) (24 ) 150 (6 ) (374 ) June 30, 2024 $ 78,936 $ 16,916 $ 46,665 $ 37,205 $ 179,722

Note 7 - Indebtedness

Note 7 - Indebtedness	3 Months Ended
	Jun. 30, 2024
Notes to Financial Statements
Debt Disclosure [Text Block]	Note 7 . Indebtedness Credit Facility On March 5, 2021, four 1 2 not 3 not On October 5, 2023, On April 5, 2024, (i) Extend the maturity of the Credit Facility to April 2029; (ii) Allow proceeds from the Credit Facility to be used to redeem some or all of the Company’s 2025 (iii) Include a $75,000 (iv) Make certain changes to the financial covenants. In conjunction with the amendment and restatement of the Credit Facility during the three June 30, 2024, third Amounts borrowed under the Credit Facility bear interest at either a base rate or a SOFR rate plus an applicable spread ranging from 1.5% to 3.5%, depending on our total net leverage ratio. The interest rate on borrowings under our line of credit as of June 30, 2024 The financial covenants in the Credit Facility as amended include a maximum leverage ratio of 4.50 to 1.00 first five 1.0 ninth 1.0 ninth 1.0 1. June 30, 2024, Term Loan We borrowed $75,000 under the Term Loan on April 5, 2024, three June 30, 2024, We are required to make quarterly principal payments on the Term Loan. For the following fiscal years ending March 31, Fiscal Year Amount Remainder of 2025 $ 2,813 2026 3,750 2027 5,625 2028 5,625 2029 7,500 Thereafter 48,750 Total Principal Remaining $ 74,063 The net carrying amount of the Term Loan was as follows: June 30, 2024 March 31, 2024 Term Loan (8.4% as of June 30, 2024) $ 74,063 $ - Less: discount and debt issuance costs (710 ) - Less: current portion (3,750 ) - Noncurrent portion $ 69,603 $ - Revolver As of June 30, 2024, June 30, 2024, We are obligated to pay quarterly unused commitment fees of between 0.20% and 0.35% of the Revolver’s aggregate principal amount, based on our leverage ratio. The balance of unamortized customary lender fees, including fees related to the April 5, 2024 June 30, 2024 March 31, 2024, Convert ible Notes On August 12, 2019, August 15, 2025, February 15 August 15 $1,000 On April 5, 2024, three June 30, 2024. June 30, 2024, Upon conversion, we will pay or deliver, as the case may not three June 30, 2024 June 30, 2024 not June 30, 2024 The net carrying amount of the Notes was as follows: June 30, 2024 March 31, 2024 Principal outstanding $ 97,500 $ 172,500 Unamortized debt issuance costs (604 ) (1,302 ) Net carrying value $ 96,896 $ 171,198 We recognized interest expense on the Notes as follows: Three Months Ended June 30, 2024 2023 Coupon interest expense at 1.375% $ 367 $ 593 Amortization of debt issuance costs 145 230 Total interest and amortization of debt issuance costs $ 512 $ 823 The effective interest rate on the Notes is approximately 1.9%.

Note 8 - Stockholders' Equity

Note 8 - Stockholders' Equity	3 Months Ended
	Jun. 30, 2024
Notes to Financial Statements
Share-Based Payment Arrangement [Text Block]	Note 8 . Stockholders' Equity Stock-Based Compensation During the three June 30, 2024 2021 Expense recognized related to stock-based compensation is as follows: Three Months Ended June 30, 2024 2023 Stock-based compensation expense $ 2,928 $ 2,968 Stock-based compensation expense, net of tax $ 2,928 $ 2,096 Stock-based compensation expense is included in cost of revenues, selling, general and administrative, and research and development expense in the accompanying unaudited Condensed Consolidated Statements of Operations. The following is a summary of stock option award activity for the three June 30, 2024 Stock Options Shares Subject to Options Weighted- Average Exercise Price per Share Weighted-Average Remaining Contractual Life (Years) Aggregate Intrinsic Value Outstanding as of March 31, 2024 194 $ 181.89 3.2 $ 26 Awards granted - - Awards forfeited or expired (13 ) 147.07 Awards exercised - - Outstanding as of June 30, 2024 181 $ 184.42 3.1 $ - The following is a summary of RSU and PSU award activity for the three June 30, 2024 Time-Based Restricted Stock Units Performance-Based Restricted Stock Units Number of Shares Weighted- Average Grant Date Fair Value per Share Number of Shares Weighted- Average Grant Date Fair Value per Share Outstanding as of March 31, 2024 76 $ 157.83 56 $ 240.96 Awards granted (1) 101 89.82 41 102.57 Awards forfeited (2 ) 154.69 - - Awards distributed (21 ) 182.89 - - Outstanding as of June 30, 2024 154 $ 109.69 97 $ 181.85 ( 1 Balances for PSUs granted are reflected at target. Outstanding time-based RSUs vest and settle in shares of our common stock on a one one three June 30, 2024 third We grant PSUs to certain key employees. The number of shares earned is determined at the end of each performance period based on Mesa's achievement of certain pre-defined targets per the related award agreement. The outstanding PSUs vest upon completion of the service period described in the award agreement. We recognize the expense relating to the performance-based RSUs based on the probable outcome of achievement of the performance targets on a straight-line basis over the service period. During the three June 30, 2024, FY25 April 1, 2024 March 31, 2027. June 18, 2024 June 18, 2027. FY25 June 18, 2024 June 18, 2027. not no

Note 9 - Earnings (Loss) Per Sh

Note 9 - Earnings (Loss) Per Share	3 Months Ended
	Jun. 30, 2024
Notes to Financial Statements
Earnings Per Share [Text Block]	Note 9 . Earnings (Loss) Per Share The following table presents a reconciliation of the denominators used in the computation of basic and diluted earnings (loss) per share: Three Months Ended June 30, 2024 2023 Net income (loss) available for shareholders $ 3,388 $ (549 ) Weighted average outstanding shares of common stock 5,397 5,372 Dilutive effect of stock options - - Dilutive effect of RSUs 27 - Fully diluted shares 5,424 5,372 Basic earnings (loss) per share $ 0.63 $ (0.10 ) Diluted earnings (loss) per share $ 0.62 $ (0.10 ) Potentially dilutive securities include stock options and both time and performance based RSUs (collectively "stock awards"), as well as common shares underlying our Notes. Stock awards are excluded from the calculation of diluted EPS if they are subject to performance conditions that have not not The following stock awards were excluded from the calculation of diluted EPS: Three Months Ended June 30, 2024 2023 Assumed conversion of the Notes 373 608 Stock awards that were anti-dilutive 209 227 Total stock awards excluded from diluted EPS 582 835 Shares underlying the Notes were excluded from the diluted EPS calculation for the three June 30, 2024 2023 three June 30, 2024 ( 7.

Note 10 - Income Taxes

Note 10 - Income Taxes	3 Months Ended
	Jun. 30, 2024
Notes to Financial Statements
Income Tax Disclosure [Text Block]	Note 10 . Income Taxes We reported an income tax provision as follows: Three Months Ended June 30, 2024 2023 Income tax expense (benefit) $ 517 $ (388 ) For interim income tax reporting, we estimate our annual effective tax rate and apply this effective tax rate to our year-to-date pre-tax income. Each quarter, our estimate of the annual effective tax rate is updated, and if the estimated effective tax rate changes, a cumulative adjustment is made. Additionally, the tax effects of significant unusual or infrequently occurring items are recognized as discrete items in the interim period in which the events occur. There is a potential for volatility in the effective tax rate due to several factors, including changes in the mix of the pre-tax income and the jurisdictions to which they relate, changes in tax laws and foreign tax holidays, settlement with taxing authorities, and foreign currency fluctuations. Our effective income tax rate was 13% for the three June 30, 2024 three June 30, 2023. three June 30, 2024 March 31, 2024.

Note 11 - Commitments and Conti

Note 11 - Commitments and Contingencies	3 Months Ended
	Jun. 30, 2024
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	Note 11 . Commitments and Contingencies We are party to various legal proceedings arising in the ordinary course of business. As of June 30, 2024 not As part of the GKE acquisition , June 30, 2024 18 may June 30, 2024. As part of the Belyntic acquisition, we agreed to pay the sellers a contingency based upon approval of contractually specified patents. The estimated fair value of the probable remaining contingent consideration was $650 as of June 30, 2024 .

Note 12 - Segment Data

Note 12 - Segment Data	3 Months Ended
	Jun. 30, 2024
Notes to Financial Statements
Segment Reporting Disclosure [Text Block]	Note 12 . S egment Information The following tables set forth our segment information: Three Months Ended June 30, 2024 2023 Revenues (a): Sterilization and Disinfection Control (b) $ 22,957 $ 15,927 Clinical Genomics 11,404 13,369 Biopharmaceutical Development 12,008 9,889 Calibration Solutions 11,801 11,460 Total revenues $ 58,170 $ 50,645 Gross profit: Sterilization and Disinfection Control (b) $ 15,558 $ 11,591 Clinical Genomics 6,490 6,728 Biopharmaceutical Development 7,959 6,433 Calibration Solutions 7,242 6,431 Gross profit $ 37,249 $ 31,183 Reconciling items: Operating expense 31,669 31,847 Operating income (loss) 5,580 (664 ) Nonoperating expense, net 1,675 273 Earnings (loss) before income taxes $ 3,905 $ (937 ) (a) Intersegment revenues are not (b) Includes post-acquisition GKE results during the three June 30, 2024 The following table sets forth inventories by reportable segment. Our chief operating decision maker is not June 30, March 31, 2024 2024 Sterilization and Disinfection Control $ 6,465 $ 7,014 Clinical Genomics 12,156 11,813 Biopharmaceutical Development 6,255 6,304 Calibration Solutions 6,891 7,544 Total inventories $ 31,767 $ 32,675

Insider Trading Arrangements

Insider Trading Arrangements shares in Thousands	3 Months Ended
	Jun. 30, 2024 shares
Insider Trading Arr Line Items
Material Terms of Trading Arrangement [Text Block]	5. Other Information The following of our directors or officers entered into written plans for the purchase or sale of our securities intended to satisfy the affirmative defense conditions of Exchange Act Rule 10b5 1 Senior Vice President of Continuous Improvement Brian Archbold June 12, 2024 The May 30, 2025, may 558
Trading Arrangement, Individual Title	Senior Vice President of Continuous Improvement
Trading Arrangement, Individual Name	Brian Archbold
Trading Arrangement Adoption Date	June 12, 2024
Rule 10b5-1 Arrangement Adopted [Flag]	true
Non-Rule 10b5-1 Arrangement Adopted [Flag]	false
Rule 10b5-1 Arrangement Terminated [Flag]	false
Non-Rule 10b5-1 Arrangement Terminated [Flag]	false
Trading Arrangement, Securities Aggregate Available Amount	558

Significant Accounting Policies

Significant Accounting Policies (Policies)	3 Months Ended
	Jun. 30, 2024
Accounting Policies [Abstract]
Description of Business [Policy Text Block]	Description of Business In this quarterly report on Form 10 We are a global leader in the design and manufacture of life sciences tools and critical quality control solutions for regulated applications in the pharmaceutical, healthcare, and medical device industries. We offer products and services to help our customers ensure product integrity, increase patient and worker safety, and improve the quality of life throughout the world. We have manufacturing operations in the United States and Europe, and our products are marketed by our sales personnel in North America, Europe, and Asia Pacific, and by independent distributors in these areas as well as throughout the rest of the world. We prefer markets in which we can establish a strong presence and achieve high gross profit margins. As of June 30, 2024 four ● Sterilization and Disinfection Control ● Clinical Genomics ● Biopharmaceutical Development ● Calibration Solutions
Basis of Accounting, Policy [Policy Text Block]	Basis of Presentation The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission and in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) for interim financial information. In the opinion of management, such unaudited information includes all adjustments, consisting of normal recurring adjustments necessary for the fair statement of our financial position and results of operations. The results of operations for interim periods are not may not no 10 10 March 31, 2024 Our fiscal year ends on March 31.
Risk and Uncertainties, Policy [Policy Text Block]	Risks and Uncertainties The preparation of financial statements requires the use of estimates and assumptions that affect the reported amounts of assets and liabilities at the reporting date and revenues and expenses during the reporting periods. These estimates represent management's judgment about the outcome of future events. The global business environment continues to be impacted by cost pressures, the overall effects of economic uncertainty on customers' purchasing patterns, high interest rates, and other factors. It is not
New Accounting Pronouncements, Policy [Policy Text Block]	Recently Issued Accounting Pronouncements In November 2023, No. 2023 07, 280 No. 2023 07 280 December 15, 2023 ( 2025 December 15, 2024 ( 2026 In December 2023, No. 2023 09, 740 No. 2023 09, December 15, 2024 ( 2026 We have reviewed all recently issued accounting pronouncements and have concluded that, other than as described above, they are either not not

Note 3 - Revenue (Tables)

Note 3 - Revenue (Tables)	3 Months Ended
	Jun. 30, 2024
Notes Tables
Disaggregation of Revenue [Table Text Block]	Three Months Ended June 30, 2024 Sterilization and Disinfection Control (1) Clinical Genomics Biopharmaceutical Development Calibration Solutions Total Consumables $ 20,396 $ 8,112 $ 3,922 $ 580 $ 33,010 Hardware and software 169 2,183 4,837 6,886 14,075 Services 2,392 1,109 3,249 4,335 11,085 Total revenues $ 22,957 $ 11,404 $ 12,008 $ 11,801 $ 58,170 Three Months Ended June 30, 2023 Sterilization and Disinfection Control Clinical Genomics Biopharmaceutical Development Calibration Solutions Total Consumables $ 13,707 $ 8,769 $ 4,486 $ 509 $ 27,471 Hardware and software 81 3,427 2,691 7,078 13,277 Services 2,139 1,173 2,712 3,873 9,897 Total revenues $ 15,927 $ 13,369 $ 9,889 $ 11,460 $ 50,645
Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas [Table Text Block]	Three Months Ended June 30, 2024 2023 United States $ 26,861 $ 26,537 China 6,559 6,113 Other 24,750 17,995 Total revenues $ 58,170 $ 50,645
Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]	Contract liabilities as of March 31, 2024 $ 15,686 Prior year liabilities recognized in revenues during the three months ended June 30, 2024 (3,805 ) Contract liabilities added during the three months ended June 30, 2024, net of revenues recognized 2,877 Contract liabilities as of June 30, 2024 $ 14,758

Note 4 - Fair Value Measureme_2

Note 4 - Fair Value Measurements (Tables)	3 Months Ended
	Jun. 30, 2024
Notes Tables
Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]	June 30, 2024 March 31, 2024 Carrying Value Fair Value (Level 2) Carrying Value Fair Value (Level 2) Notes $ 96,896 $ 92,016 $ 171,198 $ 163,013

Note 5 - Supplemental Informa_2

Note 5 - Supplemental Information (Tables)	3 Months Ended
	Jun. 30, 2024
Notes Tables
Schedule of Inventory, Current [Table Text Block]	June 30, 2024 March 31, 2024 Raw materials $ 19,031 $ 18,335 Work in process 682 1,256 Finished goods 12,054 13,084 Total inventories $ 31,767 $ 32,675
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]	June 30, 2024 March 31, 2024 Prepaid expenses $ 3,928 $ 2,932 Deposits 1,514 1,898 Prepaid income taxes 1,798 1,237 Other current assets 3,643 3,341 Total prepaid expenses and other current assets $ 10,883 $ 9,408
Schedule of Employee Related Liabilities [Table Text Block]	June 30, 2024 March 31, 2024 Bonus payable $ 2,175 $ 3,838 Wages and paid-time-off payable 3,402 3,072 Payroll related taxes 2,223 1,956 Other benefits payable 538 1,069 Total accrued payroll and benefits $ 8,338 $ 9,935
Schedule of Accrued Liabilities [Table Text Block]	June 30, 2024 March 31, 2024 Accrued business taxes $ 5,268 $ 5,557 Current operating lease liabilities 2,940 2,986 Income taxes payable 1,569 1,615 Current acquisition-related holdbacks 9,384 436 Other 3,323 2,264 Total other accrued expenses $ 22,484 $ 12,858
Other Noncurrent Liabilities [Table Text Block]	June 30, 2024 March 31, 2024 Noncurrent operating lease liabilities $ 6,299 $ 6,613 Noncurrent acquisition-related holdbacks 158 8,792 Other 124 208 Total other noncurrent liabilities $ 6,581 $ 15,613
Property, Plant and Equipment [Table Text Block]	Three Months Ended June 30, 2024 2023 Depreciation expense in cost of revenues $ 862 $ 674 Depreciation expense in operating expense 542 240 Total depreciation expense $ 1,404 $ 914

Note 6 - Goodwill and Intangi_2

Note 6 - Goodwill and Intangible Assets, Net (Tables)	3 Months Ended
	Jun. 30, 2024
Notes Tables
Schedule of Finite-Lived Intangible Assets [Table Text Block]	June 30, 2024 March 31, 2024 Gross Carrying Amount Accumulated Amortization Net Carrying Amount Gross Carrying Amount Accumulated Amortization Net Carrying Amount Customer relationships $ 189,708 $ (107,470 ) $ 82,238 $ 189,911 $ (104,528 ) $ 85,383 Other intangibles 61,140 (33,919 ) 27,221 61,161 (32,792 ) 28,369 Total finite-lived intangible assets $ 250,848 $ (141,389 ) $ 109,459 $ 251,072 $ (137,320 ) $ 113,752
Finite-Lived Intangible Assets Amortization Expense [Table Text Block]	Three Months Ended June 30, 2024 2023 Amortization in cost of revenues $ 647 $ 1,728 Amortization in general and administrative 3,414 5,492 Total amortization expense $ 4,061 $ 7,220
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]	Fiscal Year Amortization Expense Remainder of 2025 $ 13,289 2026 16,975 2027 16,319 2028 15,731 2029 15,182
Schedule of Goodwill [Table Text Block]	Sterilization and Disinfection Control Clinical Genomics Biopharmaceutical Development Calibration Solutions Total March 31, 2024 $ 79,430 $ 16,940 $ 46,515 $ 37,211 180,096 Effect of foreign currency translation (494 ) (24 ) 150 (6 ) (374 ) June 30, 2024 $ 78,936 $ 16,916 $ 46,665 $ 37,205 $ 179,722

Note 7 - Indebtedness (Tables)

Note 7 - Indebtedness (Tables)	3 Months Ended
	Jun. 30, 2024
Notes Tables
Schedule of Maturities of Long-Term Debt [Table Text Block]	Fiscal Year Amount Remainder of 2025 $ 2,813 2026 3,750 2027 5,625 2028 5,625 2029 7,500 Thereafter 48,750 Total Principal Remaining $ 74,063
Convertible Debt [Table Text Block]	June 30, 2024 March 31, 2024 Principal outstanding $ 97,500 $ 172,500 Unamortized debt issuance costs (604 ) (1,302 ) Net carrying value $ 96,896 $ 171,198
Interest Expense on Convertible Debt [Table Text Block]	Three Months Ended June 30, 2024 2023 Coupon interest expense at 1.375% $ 367 $ 593 Amortization of debt issuance costs 145 230 Total interest and amortization of debt issuance costs $ 512 $ 823
Term Loan [Member]
Notes Tables
Convertible Debt [Table Text Block]	June 30, 2024 March 31, 2024 Term Loan (8.4% as of June 30, 2024) $ 74,063 $ - Less: discount and debt issuance costs (710 ) - Less: current portion (3,750 ) - Noncurrent portion $ 69,603 $ -

Note 8 - Stockholders' Equity (

Note 8 - Stockholders' Equity (Tables)	3 Months Ended
	Jun. 30, 2024
Notes Tables
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]	Three Months Ended June 30, 2024 2023 Stock-based compensation expense $ 2,928 $ 2,968 Stock-based compensation expense, net of tax $ 2,928 $ 2,096
Share-Based Payment Arrangement, Option, Activity [Table Text Block]	Stock Options Shares Subject to Options Weighted- Average Exercise Price per Share Weighted-Average Remaining Contractual Life (Years) Aggregate Intrinsic Value Outstanding as of March 31, 2024 194 $ 181.89 3.2 $ 26 Awards granted - - Awards forfeited or expired (13 ) 147.07 Awards exercised - - Outstanding as of June 30, 2024 181 $ 184.42 3.1 $ -
Share-Based Payment Arrangement, Activity [Table Text Block]	Time-Based Restricted Stock Units Performance-Based Restricted Stock Units Number of Shares Weighted- Average Grant Date Fair Value per Share Number of Shares Weighted- Average Grant Date Fair Value per Share Outstanding as of March 31, 2024 76 $ 157.83 56 $ 240.96 Awards granted (1) 101 89.82 41 102.57 Awards forfeited (2 ) 154.69 - - Awards distributed (21 ) 182.89 - - Outstanding as of June 30, 2024 154 $ 109.69 97 $ 181.85

Note 9 - Earnings (Loss) Per _2

Note 9 - Earnings (Loss) Per Share (Tables)	3 Months Ended
	Jun. 30, 2024
Notes Tables
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	Three Months Ended June 30, 2024 2023 Net income (loss) available for shareholders $ 3,388 $ (549 ) Weighted average outstanding shares of common stock 5,397 5,372 Dilutive effect of stock options - - Dilutive effect of RSUs 27 - Fully diluted shares 5,424 5,372 Basic earnings (loss) per share $ 0.63 $ (0.10 ) Diluted earnings (loss) per share $ 0.62 $ (0.10 )
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	Three Months Ended June 30, 2024 2023 Assumed conversion of the Notes 373 608 Stock awards that were anti-dilutive 209 227 Total stock awards excluded from diluted EPS 582 835

Note 10 - Income Taxes (Tables)

Note 10 - Income Taxes (Tables)	3 Months Ended
	Jun. 30, 2024
Notes Tables
Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]	Three Months Ended June 30, 2024 2023 Income tax expense (benefit) $ 517 $ (388 )

Note 12 - Segment Data (Tables)

Note 12 - Segment Data (Tables)	3 Months Ended
	Jun. 30, 2024
Notes Tables
Schedule of Segment Reporting Information, by Segment [Table Text Block]	Three Months Ended June 30, 2024 2023 Revenues (a): Sterilization and Disinfection Control (b) $ 22,957 $ 15,927 Clinical Genomics 11,404 13,369 Biopharmaceutical Development 12,008 9,889 Calibration Solutions 11,801 11,460 Total revenues $ 58,170 $ 50,645 Gross profit: Sterilization and Disinfection Control (b) $ 15,558 $ 11,591 Clinical Genomics 6,490 6,728 Biopharmaceutical Development 7,959 6,433 Calibration Solutions 7,242 6,431 Gross profit $ 37,249 $ 31,183 Reconciling items: Operating expense 31,669 31,847 Operating income (loss) 5,580 (664 ) Nonoperating expense, net 1,675 273 Earnings (loss) before income taxes $ 3,905 $ (937 )
Schedule of Depreciation and Amortization Expense [Table Text Block]	June 30, March 31, 2024 2024 Sterilization and Disinfection Control $ 6,465 $ 7,014 Clinical Genomics 12,156 11,813 Biopharmaceutical Development 6,255 6,304 Calibration Solutions 6,891 7,544 Total inventories $ 31,767 $ 32,675

Note 2 - Significant Transact_2

Note 2 - Significant Transactions (Details Textual) - GKE Acquisition [Member] - USD ($) $ in Thousands		3 Months Ended
	Oct. 16, 2023	Jun. 30, 2024
Payments to Acquire Businesses, Gross	$ 87,187
Business Combination, Consideration Transferred, Liabilities Incurred	9,200
Proceeds from Lines of Credit	$ 71,000
Business Combination, Pro Forma Information, Revenue of Acquiree since Acquisition Date, Actual		$ 6,254
Business Combination, Pro Forma Information, Earnings or Loss of Acquiree since Acquisition Date, Actual		3,820
Inventory Step-up Cost, Increase (Decrease) During Period		778
General and Administrative Expense [Member]
Amortization		532
Cost of Revenues Related to Intangibles Acquired [Member]
Amortization		$ 110
GKE GmbH and SAL GmbH [Member]
Business Acquisition, Percentage of Voting Interests Acquired	100%
Beijing GKE Science & Technology Co. Ltd. [Member]
Business Acquisition, Percentage of Voting Interests Acquired	100%

Note 3 - Revenue (Details Textu

Note 3 - Revenue (Details Textual) - USD ($) $ in Thousands		3 Months Ended		6 Months Ended
		Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024
Revenue from Contract with Customer, Excluding Assessed Tax	[1]	$ 58,170	$ 50,645
Sterilization and Disinfection Control [Member]
Revenue from Contract with Customer, Excluding Assessed Tax				$ 58,170
Sterilization and Disinfection Control [Member] | GKE GmbH [Member]
Revenue from Contract with Customer, Excluding Assessed Tax		$ 6,254
[1]Intersegment revenues are not significant and are eliminated to arrive at consolidated totals.

Note 3 - Revenue - Disaggregati

Note 3 - Revenue - Disaggregation of Revenue (Details) - USD ($) $ in Thousands		3 Months Ended			6 Months Ended
		Jun. 30, 2024		Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Revenues	[1]	$ 58,170		$ 50,645
Sterilization and Disinfection Control [Member]
Revenues					$ 58,170
Clinical Genomics [Member]
Revenues	[2]					$ 50,645
Consumables [Member] | Transferred at Point in Time [Member]
Revenues		33,010		27,471
Hardware and Software [Member] | Transferred at Point in Time [Member]
Revenues		14,075		13,277
Service [Member] | Transferred at Point in Time [Member]
Revenues		11,085		9,897
Operating Segments [Member] | Sterilization and Disinfection Control [Member]
Revenues	[1],[3]	22,957	[4]	15,927
Operating Segments [Member] | Clinical Genomics [Member]
Revenues	[1]	11,404		13,369
Operating Segments [Member] | Biopharmaceutical Development [Member]
Revenues	[1]	12,008		9,889
Operating Segments [Member] | Calibration Solutions [Member]
Revenues	[1]	11,801		11,460
Operating Segments [Member] | Consumables [Member] | Transferred at Point in Time [Member] | Sterilization and Disinfection Control [Member]
Revenues		20,396	[4]	13,707
Operating Segments [Member] | Consumables [Member] | Transferred at Point in Time [Member] | Clinical Genomics [Member]
Revenues		8,112		8,769
Operating Segments [Member] | Consumables [Member] | Transferred at Point in Time [Member] | Biopharmaceutical Development [Member]
Revenues		3,922		4,486
Operating Segments [Member] | Consumables [Member] | Transferred at Point in Time [Member] | Calibration Solutions [Member]
Revenues		580		509
Operating Segments [Member] | Hardware and Software [Member] | Transferred at Point in Time [Member] | Sterilization and Disinfection Control [Member]
Revenues		169	[4]	81
Operating Segments [Member] | Hardware and Software [Member] | Transferred at Point in Time [Member] | Clinical Genomics [Member]
Revenues		2,183		3,427
Operating Segments [Member] | Hardware and Software [Member] | Transferred at Point in Time [Member] | Biopharmaceutical Development [Member]
Revenues		4,837		2,691
Operating Segments [Member] | Hardware and Software [Member] | Transferred at Point in Time [Member] | Calibration Solutions [Member]
Revenues		6,886		7,078
Operating Segments [Member] | Service [Member] | Transferred at Point in Time [Member] | Sterilization and Disinfection Control [Member]
Revenues		2,392	[4]	2,139
Operating Segments [Member] | Service [Member] | Transferred at Point in Time [Member] | Clinical Genomics [Member]
Revenues		1,109		1,173
Operating Segments [Member] | Service [Member] | Transferred at Point in Time [Member] | Biopharmaceutical Development [Member]
Revenues		3,249		2,712
Operating Segments [Member] | Service [Member] | Transferred at Point in Time [Member] | Calibration Solutions [Member]
Revenues		$ 4,335		$ 3,873
[1]Intersegment revenues are not significant and are eliminated to arrive at consolidated totals.[2]Revenues in the Clinical Genomics division represent transactions subsequent to the acquisition of Agena Bioscience, Inc. on October 20, 2021.[3]Includes post-acquisition GKE results during the three months ended June 30, 2024.[4]Revenues of $6,254 from GKE are included in the Sterilization and Disinfection Control division during the three months ended June 30, 2024.

Note 3 - Revenue - Revenues Fro

Note 3 - Revenue - Revenues From External Customers (Details) - USD ($) $ in Thousands		3 Months Ended		6 Months Ended
		Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Revenues	[1]	$ 58,170	$ 50,645
Sterilization and Disinfection Control [Member]
Revenues				$ 58,170
Clinical Genomics [Member]
Revenues	[2]				$ 50,645
UNITED STATES
Revenues				26,861	26,537
CHINA
Revenues				6,559	6,113
Other [Member]
Revenues				$ 24,750	$ 17,995
[1]Intersegment revenues are not significant and are eliminated to arrive at consolidated totals.[2]Revenues in the Clinical Genomics division represent transactions subsequent to the acquisition of Agena Bioscience, Inc. on October 20, 2021.

Note 3 - Revenue - Contract Lia

Note 3 - Revenue - Contract Liabilities (Details) $ in Thousands	3 Months Ended
	Jun. 30, 2024 USD ($)
Contract liabilities, balance	$ 15,686
Prior year liabilities recognized in revenues during the three months ended June 30, 2024	(3,805)
Contract liabilities added during the three months ended June 30, 2024, net of revenues recognized	2,877
Contract liabilities as of June 30, 2024	$ 14,758

Note 4 - Fair Value Measureme_3

Note 4 - Fair Value Measurements (Details Textual) $ in Thousands	3 Months Ended
	Jun. 30, 2024 USD ($)	Apr. 05, 2024 USD ($)	Mar. 31, 2024 USD ($)	Nov. 17, 2022 USD ($)	Aug. 12, 2019
Long-Term Debt	$ 74,063
GKE Acquisition [Member]
Business Combination, Hold Back Consideration Liability	9,200
Business Combination, Hold Back Consideration Liability, Fair Value	8,900
GKE Acquisition [Member] | Fair Value, Inputs, Level 3 [Member]
Business Combination, Hold Back Consideration Liability, Fair Value	8,900
Belyntic Acquisition [Member]
Business Combination, Contingent Consideration, Liability	750
Business Combination, Contingent Consideration, Liability Fair Value	650
Belyntic Acquisition [Member] | Other Long-term Liabilities [Member]
Business Combination Contingent Consideration Liability, At Acquisition Date				$ 1,500
Belyntic Acquisition [Member] | Fair Value, Inputs, Level 3 [Member]
Business Combination, Contingent Consideration, Liability Fair Value	650
Outstanding 2025 Notes [Member]
Debt Instrument, Repurchase Amount		$ 75,000
Long-Term Debt	97,500	$ 97,500
Senior Notes [Member] | The Notes [Member]
Debt Instrument, Interest Rate, Stated Percentage		1.375%			1.375%
Long-Term Debt	$ 96,896		$ 171,198
Accounts Receivable [Member] | Customer Concentration Risk [Member]
Number of Major Customers	0

Note 4 - Fair Value Measureme_4

Note 4 - Fair Value Measurements - Fair Value and Carrying Value of the Notes (Details) - Senior Notes [Member] - USD ($) $ in Thousands	Jun. 30, 2024	Mar. 31, 2024
Reported Value Measurement [Member]
Notes	$ 96,896	$ 171,198
Estimate of Fair Value Measurement [Member] | Fair Value, Inputs, Level 2 [Member]
Notes	$ 92,016	$ 163,013

Note 5 - Supplemental Informa_3

Note 5 - Supplemental Information (Details Textual) - USD ($) $ in Thousands	3 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Depreciation	$ 1,404	$ 914
GKE Acquisition [Member]
Depreciation	$ 304

Note 5 - Supplemental Informa_4

Note 5 - Supplemental Information - Inventories (Details) - USD ($) $ in Thousands	Jun. 30, 2024	Mar. 31, 2024
Raw materials	$ 19,031	$ 18,335
Work in process	682	1,256
Finished goods	12,054	13,084
Total inventories	$ 31,767	$ 32,675

Note 5 - Supplemental Informa_5

Note 5 - Supplemental Information - Prepaid and Other Current Assets (Details) - USD ($) $ in Thousands	Jun. 30, 2024	Mar. 31, 2024
Prepaid expenses	$ 3,928	$ 2,932
Deposits	1,514	1,898
Prepaid income taxes	1,798	1,237
Other current assets	3,643	3,341
Total prepaid expenses and other current assets	$ 10,883	$ 9,408

Note 5 - Supplemental Informa_6

Note 5 - Supplemental Information - Accrued Payroll and Benefits (Details) - USD ($) $ in Thousands	Jun. 30, 2024	Mar. 31, 2024
Bonus payable	$ 2,175	$ 3,838
Wages and paid-time-off payable	3,402	3,072
Payroll related taxes	2,223	1,956
Other benefits payable	538	1,069
Total accrued payroll and benefits	$ 8,338	$ 9,935

Note 5 - Supplemental Informa_7

Note 5 - Supplemental Information - Other Accrued Expenses (Details) - USD ($) $ in Thousands	Jun. 30, 2024	Mar. 31, 2024
Current operating lease liabilities	$ 2,940	$ 2,986
Income taxes payable	1,569	1,615
Current acquisition-related holdbacks	9,384	436
Other	3,323	2,264
Total other accrued expenses	22,484	12,858
Other Accrued Expenses [Member]
Accrued business taxes	$ 5,268	$ 5,557

Note 5 - Supplemental Informa_8

Note 5 - Supplemental Information - Other Noncurrent Liabilities (Details) - USD ($) $ in Thousands	Jun. 30, 2024	Mar. 31, 2024
Other	$ 6,581	$ 15,613
GKE Acquisition [Member]
Noncurrent operating lease liabilities	6,299	6,613
Noncurrent acquisition-related holdbacks	158	8,792
Other	124	208
Total other noncurrent liabilities	$ 6,581	$ 15,613

Note 5 - Supplemental Informa_9

Note 5 - Supplemental Information - Property, Plant and Equipment (Details) - USD ($) $ in Thousands	3 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Depreciation, Total	$ 1,404	$ 914
Cost of Sales [Member]
Depreciation, Total	862	674
Operating Expense [Member]
Depreciation, Total	$ 542	$ 240

Note 6 - Goodwill and Intangi_3

Note 6 - Goodwill and Intangible Assets, Net - Other Intangible Assets (Details) - USD ($) $ in Thousands	Jun. 30, 2024	Mar. 31, 2024
Gross carrying amount	$ 250,848	$ 251,072
Accumulated amortization	(141,389)	(137,320)
Net carrying amount	109,459	113,752
Customer Relationships [Member]
Gross carrying amount	189,708	189,911
Accumulated amortization	(107,470)	(104,528)
Net carrying amount	82,238	85,383
Other Intangible Assets [Member]
Gross carrying amount	61,140	61,161
Accumulated amortization	(33,919)	(32,792)
Net carrying amount	$ 27,221	$ 28,369

Note 6 - Goodwill and Intangi_4

Note 6 - Goodwill and Intangible Assets, Net - Amortization Expense for Finite-lived Intangible Assets (Details) - USD ($) $ in Thousands	3 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Amortization of acquisition-related intangibles	$ 4,061	$ 7,220
Cost of Sales [Member]
Amortization of acquisition-related intangibles	647	1,728
General and Administrative Expense [Member]
Amortization of acquisition-related intangibles	$ 3,414	$ 5,492

Note 6 - Goodwill and Intangi_5

Note 6 - Goodwill and Intangible Assets, Net - Estimated Amortization Expense (Details) $ in Thousands	Jun. 30, 2024 USD ($)
Remainder of 2025	$ 13,289
2026	16,975
2027	16,319
2028	15,731
2029	$ 15,182

Note 6 - Goodwill and Intangi_6

Note 6 - Goodwill and Intangible Assets, Net - Change in the Carrying Amount of Goodwill (Details) $ in Thousands	3 Months Ended
	Jun. 30, 2024 USD ($)
Goodwill	$ 180,096
Effect of foreign currency translation	(374)
Goodwill	179,722
Operating Segments [Member] | Sterilization and Disinfection Control [Member]
Goodwill	79,430
Effect of foreign currency translation	(494)
Goodwill	78,936
Operating Segments [Member] | Clinical Genomics [Member]
Goodwill	16,940
Effect of foreign currency translation	(24)
Goodwill	16,916
Operating Segments [Member] | Biopharmaceutical Development [Member]
Goodwill	46,515
Effect of foreign currency translation	150
Goodwill	46,665
Operating Segments [Member] | Calibration Solutions [Member]
Goodwill	37,211
Effect of foreign currency translation	(6)
Goodwill	$ 37,205

Note 7 - Indebtedness (Details

Note 7 - Indebtedness (Details Textual) $ / shares in Units, $ in Thousands					3 Months Ended
	Jun. 30, 2024 USD ($)	Apr. 05, 2024 USD ($)	Mar. 05, 2021 USD ($)	Aug. 12, 2019 USD ($) $ / shares	Jun. 30, 2024 USD ($)	Jun. 30, 2023 USD ($)	Mar. 31, 2024 USD ($)	Oct. 05, 2023 USD ($)
Long-Term Debt, Gross	$ 74,063				$ 74,063		$ 0
Long-Term Debt	74,063				74,063
Repayments of Debt					9,438	$ 8,000
Gain (Loss) on Extinguishment of Debt					3,197	$ 0
The Credit Facility Term Loan [Member]
Debt Instrument, Fee Amount	1,987				1,987
Senior Secured Credit Agreement [Member]
Debt Instrument, Term (Year)			4 years
Long-Term Debt	42,000				42,000
Line of Credit Facility, Remaining Borrowing Capacity	83,000				83,000
Repayments of Lines of Credit	3,500
Senior Secured Credit Agreement [Member] | Prepaid Expenses, Other and Other Assets [Member]
Debt Issuance Costs, Net	1,428				1,428		321
Senior Secured Credit Agreement [Member] | The Credit Facility Term Loan [Member]
Debt Instrument, Fee Amount	745				$ 745
Senior Secured Credit Agreement [Member] | Maximum [Member]
Debt Instrument, Basis Spread on Variable Rate					3.50%
Line of Credit Facility, Unused Capacity, Commitment Fee Percentage					0.35%
Senior Secured Credit Agreement [Member] | Maximum [Member] | The Credit Facility Term Loan [Member]
Line of Credit Facility, Maximum Borrowing Capacity			$ 75,000					$ 125,000
Senior Secured Credit Agreement [Member] | Minimum [Member]
Debt Instrument, Basis Spread on Variable Rate					1.50%
Fixed Charge Coverage Ratio		1.25
Senior Leverage Ratio		3.5
Line of Credit Facility, Unused Capacity, Commitment Fee Percentage					0.20%
Senior Secured Credit Agreement [Member] | Minimum [Member] | The Credit Facility Term Loan [Member]
Line of Credit Facility, Maximum Borrowing Capacity			25,000
Senior Secured Credit Agreement [Member] | Swingline Loan [Member] | Maximum [Member]
Line of Credit Facility, Maximum Borrowing Capacity			5,000
Senior Secured Credit Agreement [Member] | Revolving Credit Facility [Member]
Line of Credit Facility, Maximum Borrowing Capacity			75,000
Debt Instrument, Fee Amount	$ 1,242				$ 1,242
Senior Secured Credit Agreement [Member] | Letter of Credit [Member] | Maximum [Member]
Line of Credit Facility, Maximum Borrowing Capacity			$ 2,500
The Credit Facility Term Loan [Member]
Debt Instrument, Interest Rate, Effective Percentage	8.40%				8.40%
Debt Instrument, Covenant, Maximum Total Leverage Ratio for the First Five Testing Dates		4.5
Debt Instrument, Covenant, Maximum Total Leverage Ratio for the Sixth, Seventh, and Eighth Testing Dates		4
Debt Instrument, Covenant, Maximum Total Leverage Ratio Following the Ninth Testing date		3.5
Term Loan [Member]
Debt Instrument, Interest Rate, Effective Percentage	8.13%				8.13%
Long-Term Debt, Gross		$ 75,000
Debt Instrument, Periodic Payment, Principal					$ 937
The Notes [Member] | Senior Notes [Member]
Debt Instrument, Interest Rate, Effective Percentage	1.90%				1.90%
Long-Term Debt, Gross	$ 97,500				$ 97,500		172,500
Long-Term Debt	96,896				96,896		171,198
Debt Issuance Costs, Net	604				604		$ 1,302
Debt Instrument, Face Amount				$ 172,500
Proceeds from Convertible Debt				$ 167,056
Debt Instrument, Interest Rate, Stated Percentage		1.375%		1.375%
Debt Instrument, Convertible, Conversion Ratio Per 1,000 Principal				3.5273
Debt Instrument, Convertible, Conversion Price (in dollars per share) | $ / shares				$ 283.5
Outstanding 2025 Notes [Member]
Long-Term Debt	$ 97,500	$ 97,500			97,500
Debt Instrument, Repurchased Face Amount		75,000
Repayments of Debt		71,250
Interest Payable		$ 160
Gain (Loss) on Extinguishment of Debt					$ 3,197

Note 7 - Indebtedness - Quarter

Note 7 - Indebtedness - Quarterly Periodic Payments (Details) $ in Thousands	Jun. 30, 2024 USD ($)
Remainder of 2025	$ 2,813
2026	3,750
2027	5,625
2028	5,625
2029	7,500
Thereafter	48,750
Total Principal Remaining	$ 74,063

Note 7 - Indebtedness - Carryin

Note 7 - Indebtedness - Carrying Amount of the Term Loan (Details) - USD ($) $ in Thousands	Jun. 30, 2024	Mar. 31, 2024
Term Loan (8.4% as of June 30, 2024)	$ 74,063	$ 0
Less: discount and debt issuance costs	(710)	0
Less: current portion	(3,750)	0
Noncurrent portion	$ 69,603	$ 0

Note 7 - Indebtedness - Carry_2

Note 7 - Indebtedness - Carrying Amount of the Notes (Details) - USD ($) $ in Thousands	Jun. 30, 2024	Mar. 31, 2024
Term Loan (8.4% as of June 30, 2024)	$ 74,063	$ 0
Total Principal Remaining	74,063
The Notes [Member] | Senior Notes [Member]
Term Loan (8.4% as of June 30, 2024)	97,500	172,500
Unamortized debt issuance costs	(604)	(1,302)
Total Principal Remaining	$ 96,896	$ 171,198

Note 7 - Indebtedness - Interes

Note 7 - Indebtedness - Interest Expense on the Notes (Details) - The Notes [Member] - USD ($) $ in Thousands	3 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Coupon interest expense at 1.375%	$ 367	$ 593
Amortization of debt issuance costs	145	230
Total interest and amortization of debt issuance costs	$ 512	$ 823

Note 8 - Stockholders' Equity_2

Note 8 - Stockholders' Equity (Details Textual) shares in Thousands	3 Months Ended
	Jun. 30, 2024 $ / shares shares
The FY25 PSUs [Member] | Eligible Employees [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized (in shares)	41
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized for Service and Company Financial Performance Conditions (in shares)	23
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value, Shares Subject to Service and Company Performance (in dollars per share) | $ / shares	$ 89.82
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized, Subject to Service and Market Conditions (in shares)	18
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value, Subject to Service and Market Conditions (in dollars per share) | $ / shares	$ 119.54
The FY25 PSUs [Member] | Eligible Employees [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award Number of Shares Issued Upon Vesting, Percentage	0%
The FY25 PSUs [Member] | Eligible Employees [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award Number of Shares Issued Upon Vesting, Percentage	200%
The 2021 Equity Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized (in shares)	660

Note 8 - Stock Transactions and

Note 8 - Stock Transactions and Stock-based Compensation - Allocation of Share-based Compensation (Details) - USD ($) $ in Thousands	3 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Stock-based compensation expense	$ 2,928	$ 2,968
Stock-based compensation expense, net of tax	$ 2,928	$ 2,096

Note 8 - Stock Transactions a_2

Note 8 - Stock Transactions and Stock-based Compensation - Stock Option and Non-vested Stock Award Activity (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended	6 Months Ended	12 Months Ended
	Jun. 30, 2024	Jun. 30, 2024	Mar. 31, 2024
Options outstanding (in shares)		194
Options outstanding, weighted average exercise price (in dollars per share)	$ 181.89
Outstanding, Weighted- Average Remaining Contractual Life (Year)	3 years 1 month 6 days		3 years 2 months 12 days
Outstanding, Aggregate Intrinsic Value	$ 0	$ 0	$ 26
Options granted (in shares)		0
Awards granted, weighted average exercise price (in dollars per share)	$ 0
Options forfeited or expired (in shares)		(13)
Awards forfeited or expired, weighted average exercise price (in dollars per share)	147.07
Awards exercised (in shares)		0
Awards exercised, weighted average exercise price (in dollars per share)	$ 0
Options outstanding (in shares)	181	181
Options outstanding, weighted average exercise price (in dollars per share)	$ 184.42	$ 184.42	$ 181.89

Note 8 - Stockholders' Equity -

Note 8 - Stockholders' Equity - Restricted Stock Unit Activity (Details)	3 Months Ended
	Jun. 30, 2024 $ / shares shares
Restricted Stock Units (RSUs) [Member]
Outstanding as of March 31, 2024 (in shares) | shares	76
Outstanding as of March 31, 2024 (in dollars per share) | $ / shares	$ 157.83
Awards granted(1) (in shares) | shares	101	[1]
Awards granted(1) (in dollars per share) | $ / shares	$ 89.82	[1]
Awards forfeited (in shares) | shares	(2)
Awards forfeited (in dollars per share) | $ / shares	$ 154.69
Awards distributed (in shares) | shares	(21)
Awards distributed, weighted average grant date fair value per share (in dollars per share) | $ / shares	$ 182.89
Outstanding as of June 30, 2024 (in shares) | shares	154
Outstanding as of June 30, 2024 (in dollars per share) | $ / shares	$ 109.69
Performance Stock Units [Member]
Outstanding as of March 31, 2024 (in shares) | shares	56
Outstanding as of March 31, 2024 (in dollars per share) | $ / shares	$ 240.96
Awards granted(1) (in shares) | shares	41	[1]
Awards granted(1) (in dollars per share) | $ / shares	$ 102.57	[1]
Awards forfeited (in shares) | shares	0
Awards forfeited (in dollars per share) | $ / shares	$ 0
Awards distributed (in shares) | shares	0
Awards distributed, weighted average grant date fair value per share (in dollars per share) | $ / shares	$ 0
Outstanding as of June 30, 2024 (in shares) | shares	97
Outstanding as of June 30, 2024 (in dollars per share) | $ / shares	$ 181.85
[1]Balances for PSUs granted are reflected at target.

Note 9 - Earnings (Loss) Per _3

Note 9 - Earnings (Loss) Per Share - Computation of Net Income Per Share, Basic & Diluted (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Net income (loss)	$ 3,388	$ (549)
Weighted average outstanding shares of common stock (in shares)	5,397	5,372
Fully diluted shares (in shares)	5,424	5,372
Basic earnings (loss) per share (in dollars per share)	$ 0.63	$ (0.1)
Diluted earnings (loss) per share (in dollars per share)	$ 0.62	$ (0.1)
Share-Based Payment Arrangement, Option [Member]
Dilutive effect of shares (in shares)	0	0
Restricted Stock Units (RSUs) [Member]
Dilutive effect of shares (in shares)	27	0

Note 9 - Earnings (Loss) Per _4

Note 9 - Earnings (Loss) Per Share - Antidilutive Securities Excluded From Computation of Earnings Per Share (Details) - shares shares in Thousands	3 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Total stock awards excluded from diluted EPS (in shares)	582	835
Assumed Conversion of Convertible Debt [Member]
Total stock awards excluded from diluted EPS (in shares)	373	608
Stock Awards that were Antidilutive [Member]
Total stock awards excluded from diluted EPS (in shares)	209	227

Note 10 - Income Taxes (Details

Note 10 - Income Taxes (Details Textual)	3 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Effective Income Tax Rate Reconciliation, Percent	13%	41%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent	21%

Note 10 - Income Taxes - Provis

Note 10 - Income Taxes - Provisions for Income Taxes (Details) - USD ($) $ in Thousands	3 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Income tax expense (benefit)	$ 517	$ (388)

Note 11 - Commitments and Con_2

Note 11 - Commitments and Contingencies (Details Textual) $ in Thousands	Jun. 30, 2024 USD ($)
GKE Acquisition [Member]
Business Combination, Hold Back Consideration Liability	$ 9,200
Business Combination, Hold Back Consideration Liability, Fair Value	8,900
Belyntic Acquisition [Member]
Business Combination, Contingent Consideration, Liability Fair Value	$ 650

Note 12 - Segment Data - Operat

Note 12 - Segment Data - Operating Segment Information (Details) - USD ($) $ in Thousands		3 Months Ended			6 Months Ended
		Jun. 30, 2024		Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Revenues	[1]	$ 58,170		$ 50,645
Sterilization and Disinfection Control (b)		37,249		31,183
Operating expense		31,669		31,847
Operating income (loss)		5,580		(664)
Nonoperating expense, net		(1,675)		(273)
Sterilization and Disinfection Control [Member]
Revenues					$ 58,170
Clinical Genomics [Member]
Revenues	[2]					$ 50,645
Operating Segments [Member]
Operating expense		31,669		31,847
Operating income (loss)		5,580		(664)
Nonoperating expense, net		1,675		273
Earnings (loss) before income taxes		3,905		(937)
Operating Segments [Member] | Sterilization and Disinfection Control [Member]
Revenues	[1],[3]	22,957	[4]	15,927
Sterilization and Disinfection Control (b)	[3]	15,558		11,591
Operating Segments [Member] | Clinical Genomics [Member]
Revenues	[1]	11,404		13,369
Sterilization and Disinfection Control (b)		6,490		6,728
Operating Segments [Member] | Biopharmaceutical Development [Member]
Revenues	[1]	12,008		9,889
Sterilization and Disinfection Control (b)		7,959		6,433
Operating Segments [Member] | Calibration Solutions [Member]
Revenues	[1]	11,801		11,460
Sterilization and Disinfection Control (b)		$ 7,242		$ 6,431
[1]Intersegment revenues are not significant and are eliminated to arrive at consolidated totals.[2]Revenues in the Clinical Genomics division represent transactions subsequent to the acquisition of Agena Bioscience, Inc. on October 20, 2021.[3]Includes post-acquisition GKE results during the three months ended June 30, 2024.[4]Revenues of $6,254 from GKE are included in the Sterilization and Disinfection Control division during the three months ended June 30, 2024.

Note 12 - Segment Data - Segmen

Note 12 - Segment Data - Segment Depreciation and Amortization (Details) - USD ($) $ in Thousands	Jun. 30, 2024	Mar. 31, 2024
Total inventories	$ 31,767	$ 32,675
Operating Segments [Member] | Sterilization and Disinfection Control [Member]
Total inventories	6,465	7,014
Operating Segments [Member] | Clinical Genomics [Member]
Total inventories	12,156	11,813
Operating Segments [Member] | Biopharmaceutical Development [Member]
Total inventories	6,255	6,304
Operating Segments [Member] | Calibration Solutions [Member]
Total inventories	$ 6,891	$ 7,544